• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Cerulean promotes Eliasof to senior VP & CSO  | Personnel Moves, Oct. 26, 2016

October 26, 2016 By Sarah Faulkner

Scott EliasofCerulean promotes Eliasof to senior VP & CSO


Cerulean Pharma (NSDQ:CERU) said today that it named Scott Eliasof as senior VP and CSO, promoting him from VP of research. He joined the Waltham, Mass.-based company in 2007.

Before coming on board to Cerulean, Eliasof was the director of the chemical biology platform at the Broad Institute in Cambridge, Mass. He managed a multidisciplinary team of synthetic chemists, analytical chemists, computational scientists and software engineers. He also has held a management position at Millennium Pharmaceuticals, working on large-scale, genomics-based drug discovery.

“For the past 10 years, Scott has been one of the driving forces behind our [nanoparticle-drug conjugate] innovations, and we are pleased to expand his role at this critical time for our company,” president & CEO Christopher Guiffre said in prepared remarks. “Our versatile NDC platform created our proprietary pipeline, including CRLX101 and CRLX301, and enabled our recently-announced collaboration with Novartis, which includes potential milestone payments for up to 5 targets. We look forward to Scott’s leadership and continued contributions as we advance this pipeline and platform.”

Last week, Cerulean said it inked a deal with Novartis to develop nanoparticle-drug conjugates. Cerulean will receive $5 million plus funding for 5 full-time equivalents to develop NDC candidates, according to the agreement, as well as preclinical, clinical, regulatory, and sales milestones for each target.

The company may also earn single-digit to low double-digit tiered royalties on net sales for each NDC product, following regulatory approval. Swiss biotech giant Novartis is responsible for further development and commercialization of NDC products that result from the collaboration.

Read more

Filed Under: Nanoparticles, Personnel Tagged With: Cerulean Pharma Inc.

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS